KalVista Pharmaceuticals (KALV) Current Leases (2017 - 2025)
KalVista Pharmaceuticals recorded quarterly Current Leases of $2.1 million in Q3 2025, up 7.33% quarter-over-quarter from $2.0 million in Q2 2025, and up 67.88% year-over-year from $1.3 million in Q3 2024.
KalVista Pharmaceuticals' Current Leases history runs 9 years deep, the most recent figure standing at $2.1 million for Q3 2025.
- In Q3 2025, Current Leases rose 67.88% year-over-year to $2.1 million; the TTM figure through Jul 2025 stood at $2.1 million (up 67.88% YoY), while the FY2025 annual figure was $2.0 million, up 51.84% from the prior year.
- Current Leases came in at $2.1 million for Q3 2025 at KalVista Pharmaceuticals, up from $2.0 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $2.1 million in Q3 2025 to a low of $592000.0 in Q1 2021.
- A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Current Leases.
- On a YoY basis, Current Leases climbed as much as 120.38% in 2021 and fell as far as 0.0% in 2021.
- KalVista Pharmaceuticals' Current Leases stood at $930000.0 in 2021, then gained by 10.32% to $1.0 million in 2022, then increased by 11.89% to $1.1 million in 2023, then rose by 26.48% to $1.5 million in 2024, then soared by 46.14% to $2.1 million in 2025.
- According to Business Quant data, Current Leases over the past three periods registered $2.1 million, $2.0 million, and $1.5 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 2.12 Mn |
| Apr 30, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Oct 31, 2024 | 1.44 Mn |
| Jul 31, 2024 | 1.26 Mn |
| Apr 30, 2024 | 1.30 Mn |
| Jan 31, 2024 | 1.19 Mn |
| Oct 31, 2023 | 1.15 Mn |
| Jul 31, 2023 | 1.12 Mn |
| Apr 30, 2023 | 1.09 Mn |
| Jan 31, 2023 | 1.06 Mn |
| Oct 31, 2022 | 1.03 Mn |
| Jul 31, 2022 | 997,000.00 |
| Apr 30, 2022 | 977,000.00 |
| Jan 31, 2022 | 1.01 Mn |
| Oct 31, 2021 | 930,000.00 |
| Jul 31, 2021 | 905,000.00 |
| Apr 30, 2021 | 863,000.00 |
| Jan 31, 2021 | 592,000.00 |
| Oct 31, 2020 | 422,000.00 |
| Jul 31, 2020 | 513,000.00 |
| Apr 30, 2020 | 588,000.00 |
| Jan 31, 2020 | 592,000.00 |
| Oct 31, 2019 | 602,000.00 |
| Jul 31, 2019 | 580,000.00 |
| Apr 30, 2019 | 54,000.00 |
| Jan 31, 2019 | 109,000.00 |
| Oct 31, 2018 | 157,000.00 |
| Jul 31, 2018 | 214,000.00 |
| Apr 30, 2018 | 221,000.00 |
| Jan 31, 2018 | 222,000.00 |
| Oct 31, 2017 | 220,000.00 |
| Jul 31, 2017 | 202,000.00 |